Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avantis International Small Cap Value ETF (AVDV) vs AstraZeneca plc (AZN) Price & Performance

Avantis International Small Cap Value ETFTrade
AstraZeneca plcTrade

Price performance (Past 24H)

Key statistics

Avantis International Small Cap Value ETF vs AstraZeneca plc — how do they compare? Avantis International Small Cap Value ETF trades at $109.61, while AstraZeneca plc trades at $158.04 (market cap $248.14B). The key difference: AstraZeneca plc pays a 2.01% dividend while Avantis International Small Cap Value ETF pays none, and Avantis International Small Cap Value ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.

AVDVAZN
Sector
Sector/ThematicHealth
52-Week High
$110.40$209.48
52-Week Low
$83.89$147.06
Market Cap
$248.14B
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avantis International Small Cap Value ETF

No Aura AI signal available yet.

AstraZeneca plc

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Avantis International Small Cap Value ETF

AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.

Read more on AVDV

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN